With further research, allogeneic CAR T-cell therapy may help overcome the cost and production time barriers currently associated with autologous CAR T-cell therapy.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an effective type of immunotherapy, particularly in the treatment landscape surrounding hematological cancers. But harvesting autologous CAR T-cells to genetically modify and reinfuse—the typical manufacturing process—is notoriously expensive, tedious, and can be difficult in patients with high tumor burden and those who have had previous tumor-reductive treatment.
Allogeneic, aka off-the-shelf, CAR T-cell therapy using donor cells could potentially overcome some of the drawbacks of autologous CAR T-cell therapy, and a recent case study published in ImmunoMedicine showed that this method could be effective with manageable adverse effects, although the disease maintenance period was short.
Human leukocyte antigen (HLA) matched allogeneic CAR T cells currently hold the most promise in making CAR T-cell therapy more accessible, but only a small number of patients with B-cell malignancies have received treatment with donor-derived CAR T cells. This especially includes patients who relapsed post-transplantation, and most have achieved complete remission (CR) or partial remission (PR) and had relatively infrequent instances of graft-versus-host disease (GVHD) and other toxicities.
Study authors recruited a 53-year-old female patient who presented with relapsed/refractory acute B-cell lymphoblastic leukemia and had received a series of chemotherapies from October 2018 to August 2019. The patient’s tumor burden was as high as 85% at relapse. Given the likelihood of failure with manufacturing autologous CAR T cells due to low quantities, she was recruited to the authors’ clinical trial of HLA-matched allogeneic CAR-T cell therapy to avoid delays in treatment.
The patient received a cycle of hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (Hyper-CVAD Part A), followed by fludarabine and cyclophosphamide for lymphodepletion. Then, HLA-matched allogeneic anti-CD19 CAR T cells donated by her sister were infused at a dose of 3.3 × 106/kg.
Shortly after infusion, the patient developed recurrent fevers, severe headache, and elevated cytokine levels. CAR T cells and non–CAR T cells expanded exponentially. The symptoms were a result of Grade 2 cytokine release syndrome, which mostly resolved after 10 days of supportive care, antibiotics, and antifungal therapy. There were no symptoms of graft-versus-host disease (GVHD) or immune effector cell-associated neurotoxicity syndrome.
On day 10, cerebrospinal fluid (CSF) analysis confirmed central nervous system leukemia and cytokine levels higher than in blood samples. Flow cytometry analysis on day 10 showed effective CAR T-cell expansion in CSF. Antiemetic drugs and mannitol were added to the treatment regimen, and on day 14, CSF contained no leukemia cells. The patient was in CR and tested negative for minimal residual disease (MRD). She also tested negative for both the fusion gene BCR-ABL and T315I mutation.
Fifteen days post-infusion, the patient was discharged from the hospital and prepared for allogeneic hematopoietic stem cell transplantation. A bone marrow examination 35 days after CAR T-cell therapy infusion showed relapse and MRD level increase.
Despite the short remission period in this case study and the high relapse rate seen overall in allogeneic CAR T-cell therapy so far, the efficacy of the treatment and manageable toxicity are indicators that this manufacturing method is worth further study to overcome these hurdles.
“The inability of allogeneic T cells to maintain long-term immune surveillance might be attributed to the recognition and elimination by the host immune cells,” study authors wrote. “It might also associate with severe lymphopenia, the number of allogeneic CAR T cells, and the degree of HLA-matching.”
One potential route is using allogeneic CAR T-cell therapy to condition patients ahead of hematopoietic stem cell transplantation or using a combination of allogeneic and autologous CAR T cells in patients with high tumor burden whose disease is chemorefractory.
Overall, further research could make allogeneic CAR T-cell therapy a viable alternative to costly and time-consuming autologous CAR T-cells therapy manufacturing, the study authors conclude.
Reference
Huang Y, Tan Su Yin E, Wei G, et al. HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden. ImmunoMedicine. Published online March 27, 2022. doi:10.1002/imed.1032
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More